Mallinckrodt to Acquire Sucampo for $1.2B

Mallinckrodt said today it has agreed to acquire Sucampo Pharmaceuticals for approximately $1.2 billion, including debt, in a deal designed to strengthen the buyer’s specialty pharma business.The acquisition will add to Mallinckrodt the commercial and development assets of Sucampo—including the marketed constipation treatment Amitiza ® (lubiprostone) and a pipeline that includes two rare disease treatments.Amitiza is a chloride channel activator designed to increase fluid secreti